Pages that link to "Q51590269"
Jump to navigation
Jump to search
The following pages link to Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives (Q51590269):
Displaying 50 items.
- Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension (Q22011018) (← links)
- Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells (Q22253424) (← links)
- Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review (Q24561401) (← links)
- Ca(2+)-sensitizing effect is involved in the positive inotropic effect of troglitazone (Q28345773) (← links)
- PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1 (Q28578260) (← links)
- Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-gamma via an interaction with Sp1 in vascular smooth muscle cells (Q28580328) (← links)
- A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs (Q28609826) (← links)
- Pharmacological peroxisome proliferator-activated receptorgamma ligands: emerging clinical indications beyond diabetes (Q30977623) (← links)
- Cardiovascular effects of troglitazone (Q33543124) (← links)
- Troglitazone: a review of its use in the management of type 2 diabetes mellitus (Q33588554) (← links)
- Thiazolidinediones: a new class of antidiabetic drugs (Q33607634) (← links)
- Effects of Low-Molecular-Weight Fucoidan and High Stability Fucoxanthin on Glucose Homeostasis, Lipid Metabolism, and Liver Function in a Mouse Model of Type II Diabetes (Q33612248) (← links)
- Recent developments in oral hypoglycemic agents (Q33650432) (← links)
- Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension (Q33692662) (← links)
- Insulin resistance and systemic hypertension (Q33694796) (← links)
- Impaired peroxisome proliferator-activated receptor-gamma contributes to phenotypic modulation of vascular smooth muscle cells during hypertension (Q33810041) (← links)
- Indications for treatment of asymptomatic carotid stenosis. (Q33873441) (← links)
- Pharmacotherapy of type 2 diabetes mellitus (Q33992531) (← links)
- A rational approach to drug therapy of type 2 diabetes mellitus (Q33993685) (← links)
- Insulin action in vascular endothelium: potential mechanisms linking insulin resistance with hypertension (Q34166377) (← links)
- Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins (Q34310282) (← links)
- Antioxidant U74389G improves glycerol-induced acute renal failure without affecting PPARgamma gene (Q34584762) (← links)
- The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications (Q34698743) (← links)
- Metabolic and additional vascular effects of thiazolidinediones. (Q34716953) (← links)
- Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice (Q34764232) (← links)
- Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus (Q34977225) (← links)
- Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets (Q35023612) (← links)
- Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig (Q35027247) (← links)
- Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al. (Q35061696) (← links)
- The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in type 2 diabetes with particular focus on the emerging role of the thiazolidinediones (Q35156068) (← links)
- Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence (Q35162317) (← links)
- Peroxisome proliferator-activated receptors and the cardiovascular system (Q35173859) (← links)
- Cardiometabolic syndrome: pathophysiology and treatment (Q35209082) (← links)
- Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease (Q35212563) (← links)
- Type 2 diabetes, cardiovascular risk, and the link to insulin resistance (Q35557355) (← links)
- Physiology, genetics, and cardiovascular disease: focus on African Americans (Q35741743) (← links)
- Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management (Q35765168) (← links)
- Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma (Q35835330) (← links)
- The impact of antidiabetic therapies on cardiovascular disease (Q36025991) (← links)
- Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. (Q36068458) (← links)
- Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension? (Q36223165) (← links)
- Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus (Q36283803) (← links)
- Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? (Q36320556) (← links)
- PPAR-gamma agonists and diabetic nephropathy (Q36326399) (← links)
- Should we quantify insulin resistance in patients with renal disease? (Q36341789) (← links)
- Can PPARgamma agonists have a role in the management of obesity-related hypertension? (Q36483455) (← links)
- Thiazolidinediones: effects on insulin resistance and the cardiovascular system (Q36484662) (← links)
- The complex role of PPARgamma in renal dysfunction in obesity: managing a Janus-faced receptor (Q36485238) (← links)
- The role of PPARs in the microvascular dysfunction in diabetes. (Q36511476) (← links)
- The effects of thiazolidinediones on blood pressure levels - a systematic review (Q36545395) (← links)